Comparative analysis of three treatment approaches for primary immune thrombocytopenic purpura; prednisolone with thrombopoietin, prednisolone alone, and pulse methylprednisolone; a randomized clinical trial

Mahmoud Dehghani-Ghorbi ¹ , Reyhaneh Azimi ², Niloufar Taherpour ³ , Soheila Sadeghi ² , Sina Homaee ⁴ * , Farnaz Saberian ² *

Cited by CrossRef: 2

1- Cuker A, Terrell D, Sowdagar H, Arnold D, Audia S, Bussel J, González-López T, Grace R, Masias C, McCrae K, Mitrovic M, Neunert C, Panch S, Shah S, Shy B, VandeVelde J, Cines D, Vesely S. American Society of Hematology 2026 guidelines for immune thrombocytopenia: initial and second-line therapy for adults with primary ITP. 2026;10(20):7076 [Crossref]

2- Naghinezhad J, Mohajerian A, Ahadi S, Khodakarim N, Hamblin M, Rezaeeyan H. When GPVI Goes Rogue: Pathogenesis and Therapeutic Horizons in ITP. Expert Rev Mol Med. 2026;28 [Crossref]

3- Jiang D, Kuter D. The hunt for a cure: modern medical approaches for immune thrombocytopenia. Expert Review of Hematology. 2026;19(7):705 [Crossref]